CCC publication: A phase III, double-blind,randomized study of nivolumab(NIVO) and ipilimumab (IPI), nivomonotherapy or placebo plustransarterial chemoembolization(TACE) in patients withintermediate-stage hepatocellularcarcinoma (HCC)

Citation: Journal of Clinical Oncology. 2021, 39(3)
Author: Sangro B.; Harding J.J.; Johnson M.; Palmer D.H.; Edeline J.; Abou-Alfa G.K.; Cheng A.-L.; Decaens T.; El Khoueiry A.B.; Finn R.S.; Galle P.R.; Park J.-W.; Yau T.; Begic D.; Shen Y.; Neely J.; Sama A.R.; Kudo